Shapely Review: What Its GLP-1 Program Documents—and What the Evidence Does Not Establish

A medication study can tell you something about a studied treatment. It cannot tell you whether a particular telehealth company coordinates care well, bills clearly or delivers the same formulation evaluated in that study. That distinction matters with Shapely, whose website combines insurance-supported weight management, branded drug listings and self-pay compounded injections. The useful evidence question is not simply whether semaglutide or tirzepatide has been studied; it is what Shapely actually offers and which claims its documentation supports.

Public pages consulted October 19, 2026 describe a substantive care program: video consultations, monthly follow-up, dietitian access, prescription assistance and app-based support. They also disclose medication and laboratory charges outside membership. However, different pages give different laboratory lookback periods and Medicare explanations, while insured membership pricing is not uniform. This review separates documented service features from commercial claims, clinical research and unresolved details. It is a documentary assessment, not a test of Shapely’s care or an independent verification of its insurance networks.

At a glance

Documented service area: Shapely advertises care for adults 18 and older in California, Florida, New York and Texas; nationwide expansion is described as future.
Sources: [8]
Membership is not the medication price: Self-pay membership is advertised at $49 for the first month and $99 monthly afterward. Medicines and labs are excluded.
Sources: [8]
Compounded injection pricing: The advertised starting prices of $99/month for semaglutide and $166/month for tirzepatide refer to specific three-month packages; membership is additionally required.
Sources: [6] [10]
Regulatory distinction: Shapely acknowledges that compounded medicines are not FDA approved and describes them as self-pay only, without insurance reimbursement.
Sources: [6]
Conflicting laboratory windows: The main page accepts laboratory results from the preceding six months, while the Medicare page says 12 months.
Sources: [8] [9]

Start with the service, not the medication headline

Shapely’s terms identify the business as Zaghi Medical, Inc., doing business as Shapely. Its advertised service area covers adults age 18 and older in California, Florida, New York and Texas. A statement about expanding to all 50 states is a future-facing claim, not evidence of current nationwide access. The initial process asks for insurance information and health goals so the company can check coverage before a video consultation with an assigned clinician.

The membership offering includes monthly video visits, prescriptions when appropriate, help obtaining insurance coverage, assistance locating medicines at local pharmacies, individual dietitian access and unlimited support through chat and the app. These are meaningful descriptions of the intended service. They do not establish appointment availability, response times, continuity with the same clinician or the depth of each encounter. The consulted documentation does not give firm timelines for the first visit or support replies.

The terms expressly say that a prescription is not guaranteed. They also exclude DEA-controlled or scheduled medicines and certain other drugs with abuse potential. For people who are not suitable candidates for GLP-1 treatment, Shapely describes alternatives including other medicines, lifestyle modification and continuous glucose monitoring. That makes the documented business broader than a prescription checkout, although the public material does not establish a complete intake protocol or provider-specific clinical eligibility criteria.

Sources: [7] [8]

A drug catalog is not a clinical evidence dossier

Shapely’s catalog names Oral Wegovy, Ozempic and Wegovy under semaglutide, and Zepbound and Mounjaro under tirzepatide. It also lists Foundayo as orforglipron and Contrave as bupropion and naltrexone. These are descriptions of the provider’s catalog, not independent confirmation here of every listing’s regulatory status, availability or suitability. An “insurance accepted” label likewise does not establish that a particular plan covers the medicine for a particular patient.

Separately, Shapely markets compounded semaglutide and tirzepatide injections. The distinction between a branded product and a compounded preparation should remain visible throughout the decision. FDA approval attaches to a specific product, not to Shapely or to a pharmacy merely because it prepares a medicine with a familiar ingredient name. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions.

STEP 1 and SURMOUNT-1 provide randomized trial evidence for specific studied subcutaneous treatments in adults without diabetes. They are not studies of Shapely’s service, its compounded preparations or every route shown in its catalog. Nor can separate trials be treated as a direct head-to-head comparison. The distinction between a clinical trial and a company performance report is especially important when interpreting medication marketing beside a clinic’s enrollment button.

Sources: [8] [6] [10] [1] [3] [4]

Compounding disclosures answer some questions, not all

Shapely says it works exclusively with state-licensed 503A and 503B compounding pharmacies operating under established safety and quality standards. It describes compounded prescriptions as customized after an individual clinical evaluation, potentially using formulations or strengths not commercially available. Those are provider statements, not independently checked pharmacy credentials. The consulted text does not identify the pharmacies by name or supply their licenses, leaving readers unable to trace a prospective preparation to a specific facility.

The website explicitly acknowledges that compounded medicines are not FDA approved. FDA explains that these preparations do not undergo its premarket review for safety, effectiveness and quality. That absence of approval does not, by itself, prove clinical inequivalence or settle whether an individual preparation is appropriate. FDA recommends compounded drugs when a patient’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy.

Before paying, a useful request is the dispensing pharmacy’s identity and the exact formulation and presentation proposed for the prescription. The public documentation does not establish those particulars for an individual order. FDA has also received reports of measurement or administration errors involving compounded GLP-1 medicines, including some associated with hospitalization. Instructions should therefore be clarified with the prescriber or pharmacist, rather than reconstructed from prices, marketing descriptions or a review.

Sources: [6] [1]

Read the injection prices alongside the separate membership

Shapely’s self-pay membership advertises a $49 first month, followed by $99 monthly. Medication and laboratories are separate. Its injection pages lead with semaglutide “as low as $99/month” and tirzepatide “as low as $166/month,” but those amounts correspond to particular three-month packages, not universal month-to-month medication prices. The table preserves the different options without adding membership to them or assuming which category a clinician would prescribe.

The semaglutide page says shipping, syringes and alcohol pads are included in its medication pricing. Both injection pages require membership to access medication, and Shapely says compounded medicines are self-pay only and not reimbursed by insurance. Package duration does not establish the quantity dispensed, delivery schedule or a minimum membership commitment. The consulted text also does not establish when package totals are collected, so the monthly equivalents should not be read as confirmed installment arrangements.

Shapely advertises savings of up to 33% on three-month packages and offers Affirm and Klarna. Those are commercial claims and payment options, not evidence of clinical benefit or favorable financing terms for every applicant. Interest, eligibility and other financing conditions are not explained in the consulted material. Likewise, the introductory membership discount should not be confused with an introductory medication price: tirzepatide’s starter package and low-to-mid refill package carry different stated totals.

Advertised compounded injection prices; membership is required separately
Option	Semaglutide injection	Tirzepatide injection
Monthly, low-to-mid category	$139/month	$249/month
Monthly, high category	$179/month	$299/month
Three-month starter package	$99/month equivalent; $297 total	$166/month equivalent; $498 total
Three-month low-to-mid refill	$99/month equivalent; $297 total	$199/month equivalent; $597 total
Three-month high-category package	$159/month equivalent; $477 total	$279/month equivalent; $837 total

Sources: [8] [6] [10]

Insurance claims need plan-level confirmation

Shapely says it is in network with Medicare and most PPO plans, naming Aetna, Blue Shield and United among examples. This review did not independently verify those network statements. The main page advertises a $9 first-month membership when paying with insurance, while the UnitedHealthcare page states $49 monthly plus applicable copays and deductibles. The documentation does not uniformly establish the renewal price after the $9 promotion across insurance arrangements.

The website explains that insurance-based visits can still involve copays, deductibles and coinsurance, alongside membership charges for app access, chat, education, tracking and medication-location assistance. Its statement that commercial-insurance medication copays are typically $25 monthly includes an explicit warning that they can be higher. The UnitedHealthcare page also says drug coverage varies by plan and may require prior authorization or proof of medical necessity; Shapely offers assistance with that process, not guaranteed approval.

Medicare information needs particular reconciliation. A dedicated page advertises care from $15 monthly, or free with secondary insurance, under a “Co-pays only” heading; that is not a medicine price. It also claims eligible Part D patients can obtain named medicines for $50 monthly through a Medicare GLP-1 Bridge program from July 1, 2026. The main page instead describes Medicare coverage in terms of diabetes, cardiovascular disease and obstructive sleep apnea. The Bridge claim was not externally verified here and should not be treated as universal coverage.

Sources: [8] [5] [9]

Labs and follow-up reveal the practical care model

The main page strongly recommends recent laboratory testing but says it is not required before most weight-loss medicines. It offers to order tests or accept results completed within six months before enrollment. The Medicare page gives a 12-month window instead. These statements should not be combined into a single universal rule. A prospective patient should ask which results the assigned clinician requires, how old they may be and whether any additional testing will be ordered.

For uninsured patients, Shapely advertises a flat $75 laboratory option requiring an in-person blood draw at Labcorp. Membership does not include labs; the pricing explanation describes them as typically insurance-covered or $75. The cellular-enabled scale is another conditional feature: it is advertised for use during the program but is unavailable when Aetna or Cigna is the primary insurer. Neither the scale nor laboratory access should be assumed identical across payment arrangements.

Monthly clinician video visits and dietitian access give Shapely a documented follow-up structure beyond medication fulfillment. What remains unestablished is how concerns are triaged between appointments and how quickly someone responds. NIDDK describes follow-up as assessing response and tolerability, not merely continuing prescriptions. The practical questions in our guide to clinical follow-up can help distinguish an advertised visit schedule from the individualized care responsibilities that need clarification.

Sources: [8] [9] [2]

Pharmacy choice and shipping leave a responsibility gap

Shapely’s terms say that a patient who receives a prescription can instruct the company or clinician to transmit it to the pharmacy of the patient’s choice. The service also advertises help finding medicines at local pharmacies. Separately, it offers help accessing manufacturer self-pay programs, specifically NovoCare for Wegovy and Lilly Direct for Zepbound, with potential discounts subject to eligibility. Shapely states that it is not affiliated with Novo Nordisk, Eli Lilly or their patient programs.

Both compounded injection pages advertise free two-day shipping. That is a shipping claim, not a promise that medication arrives two days after enrollment. Clinical review, prescribing, pharmacy preparation and dispatch may precede transit, and their timelines are not established in the consulted documentation. Refrigerated transport, tracking, delivery restrictions and procedures for lost, damaged or delayed shipments are also not specified. Free shipping does not mean free medication or a documented end-to-end delivery guarantee.

Those missing details matter most when a delivery appears unsuitable for use. FDA explicitly recommends not using an injectable GLP-1 medicine that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. Before ordering, ask which party handles that call and what replacement or resolution process applies. Our guide to reading shipping claims carefully explains why transit advertising is different from evidence about temperature control and delivery accountability.

Sources: [7] [8] [6] [10] [1]

Accountability and outcome claims deserve separate scrutiny

The terms contain an unresolved inconsistency about clinical relationships. One passage describes professionals employed or contracted by Shapely; another says Shapely does not employ, supervise or control the professionals providing care and disclaims responsibility for care quality or appropriateness. Those statements do not provide a clear account of the relationship. A useful pre-enrollment question is which entity provides treatment, who employs or contracts with the clinician and where clinical complaints are directed.

Communication and exit terms also need attention. Shapely warns that text messages and emails may not be encrypted and could be intercepted. Although chat and app support are advertised, the reviewed material does not establish a complete communications protocol. Nor does the consulted terms text, which included an omitted middle section, establish automatic renewal, cancellation deadlines, refund eligibility, medication returns or early departure from a three-month package. Missing documentation is not evidence that cancellation or refunds are available on particular terms.

Finally, Shapely says customer testimonials are shared with permission and that customers were compensated for usage rights; it adds that results vary. Those disclosures are relevant when weighing promotional stories. Testimonials do not establish a measured program-wide outcome or adverse-event rate, and this review found no basis in the consulted material to assign one. Service descriptions, customer narratives and randomized medication trials answer different questions and should not be blended into a single claim of provider effectiveness.

Sources: [7] [8] [3] [4]

Questions & answers

Can I join Shapely from any state?

The consulted page lists California, Florida, New York and Texas for adults 18 and older. It describes national expansion as forthcoming, not completed. Being in a listed state does not itself establish clinical eligibility, insurance coverage or a guaranteed prescription. Confirm current service availability before paying.

Sources: [8] [7]

Does Shapely’s $99 semaglutide price include membership?

No. The $99 monthly equivalent applies to specific three-month compounded semaglutide packages with a stated $297 total. Membership is required separately. The self-pay membership advertises $49 for month one and $99 monthly afterward. The standalone monthly semaglutide options are $139 for the low-to-mid category and $179 for the high category.

Sources: [6] [8]

Will Shapely guarantee insurance payment for my medicine?

No coverage guarantee is established. Shapely offers coverage checks and prior-authorization assistance, but its UnitedHealthcare page says coverage depends on the plan and may require evidence of medical necessity. Consultation coverage and medication coverage are separate questions. Ask for membership charges, visit cost-sharing and medication costs as distinct items.

Sources: [5] [8]

Can I use laboratory results I already have?

Possibly, but the website gives two windows: six months on the main page and 12 months on the Medicare page. Ask which applies to your enrollment and which tests are needed. Shapely also advertises a $75 laboratory option for uninsured patients, with the blood draw performed at a Labcorp location.

Sources: [8] [9]

Are Shapely’s compounded injections FDA approved?

No. Shapely acknowledges that compounded medicines are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not prove clinical inequivalence, but branded-product trial results do not establish results for Shapely’s compounded preparations. Request the exact formulation and pharmacy identity.

Sources: [6] [1] [3] [4]

Can I cancel a three-month package and get a refund?

The consulted documentation does not establish that right or its conditions. Package length does not by itself prove a minimum membership commitment, and cancellation would not automatically mean a refund. Obtain written terms covering renewal, cancellation timing, unused medication, package charges and any financing agreement before purchasing.

Sources: [7] [6] [10]

Our assessment

Shapely documents a broader service than medication fulfillment alone: monthly video visits, dietitian access, insurance assistance and ongoing app support are meaningful features to evaluate. Its separate medication pricing is also sufficiently specific to compare options without relying on starting-price headlines. The limits are consequential, however: pharmacy identities, package payment timing, exit terms and response standards remain unclear, while Medicare, laboratory and clinical-relationship statements need reconciliation. Clinical trials support conclusions about studied treatments, not Shapely’s performance or its compounded products. A reasonable next step is to obtain an individualized written cost breakdown, exact prescription and pharmacy details, and clear responsibility and cancellation terms—not to treat the website’s medication listings as proof of provider outcomes.

Visit Shapely’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Shapely Review: What Its GLP-1 Program Documents—and What the Evidence Does Not Establish

At a glance

01Start with the service, not the medication headline

02A drug catalog is not a clinical evidence dossier

03Compounding disclosures answer some questions, not all

04Read the injection prices alongside the separate membership

05Insurance claims need plan-level confirmation

06Labs and follow-up reveal the practical care model

07Pharmacy choice and shipping leave a responsibility gap

08Accountability and outcome claims deserve separate scrutiny